

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> Kind Attn.: Famroze Pochara Asst. Vice President
Date: February 17, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated February 17, 2017, titled "Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **Cadila Healthcare Limited**


Upen H. Shah
Company Secretary



Encl.: As above

Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray

Ahmedabad, 17 February 2017

Zydus Cadila has received the final approval from the USFDA to market Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate Spray, 0.05%.

Fluconazole Tablets USP which are used to treat fungal infections will be produced at the group's formulations manufacturing facility at Baddi.

Clobetasol Propionate Spray, used in the treatment of various skin disorders will be manufactured at the group's dedicated Topical plant located at Changodar, Ahmedabad.

The group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
